RSC Medicinal Chemistry

rsc.li/medchem

The Royal Society of Chemistry is the world's leading chemistry community. Through our high impact journals and publications we connect the world with the chemical sciences and invest the profits back into the chemistry community.

IN THIS ISSUE

ISSN 2632–8682 CODEN RMCSCX 14(10) 1829–2116 (2023)



Cover
See Hirokazu Tamamura *et al.*, pp. 1973–1980.
Image reproduced by permission of Hirokazu Tamamura from *RSC Med. Chem.*, 2023, **14**, 1973.

REVIEWS





RSC Medicinal Chemistry (electronic: ISSN 2632-8682) is published 12 times a year by the Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge, UK CB4 0WF.

All orders, with cheques made payable to the Royal Society of Chemistry, should be sent to the Royal Society of Chemistry Order Department, Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge, CB4 0WF, UK
Tel +44 (0)1223 432398; E-mail **orders@rsc.org**

2023 Annual (electronic) subscription price: £1643; US$2435. Customers in Canada will be subject to a surcharge to cover GST. Customers in the EU subscribing to the electronic version only will be charged VAT.

If you take an institutional subscription to any Royal Society of Chemistry journal you are entitled to free, site-wide web access to that journal. You can arrange access via Internet Protocol (IP) address at **www.rsc.org/ip**

Customers should make payments by cheque in sterling payable on a UK clearing bank or in US dollars payable on a US clearing bank.

RSC Medicinal Chemistry

rsc.li/medchem

RSC Medicinal Chemistry publishes significant research and review articles in medicinal chemistry and related drug discovery science.

Information for Authors

Full details on how to submit material for publication in RSC Medicinal Chemistry are given in the Instructions for Authors (available from http://**www.rsc.org/authors**). Submissions should be made via the journal's homepage: **rsc.li/medchem**

Authors may reproduce/republish portions of their published contribution without seeking permission from the Royal Society of Chemistry, provided that any such republication is accompanied by an acknowledgement in the form: (Original Citation)–Reproduced by permission of the Royal Society of Chemistry.

ROYAL SOCIETY OF CHEMISTRY

REVIEWS







RESEARCH ARTICLES



1981



Design, synthesis, and anti-hepatocellular carcinoma of thiopyrimidine/chalcone hybrids as dual STAT3/STAT5 inhibitors

Najla Altwaijry, Rehab Sabour, Mona H. Ibrahim, Omkulthom Al kamaly, Omeima Abdullah and Marwa F. Harras*

1992



Optimization of the 2-arylquinazoline-4(3*H*)one scaffold for a selective and potent antitrypanosomal agent: modulation of the mechanism of action through chemical functionalization

Angel H. Romero,* Elena Aguilera, Lourdes Gotopo, Gustavo Cabrera, Belén Dávila and Hugo Cerecetto

2007



Exploration of tricyclic heterocycles as core structures for RIOK2 inhibitors

Huilan Xiong, Qiuchun Yu, Haowen Ma, Xiuwen Yu, Yifan Ouyang, Zhi-Min Zhang, Wei Zhou,* Zhang Zhang* and Qian Cai*

2012



Design, synthesis, electrochemistry and anti-trypanosomatid hit/lead identification of nitrofuranylazines

Maryna Saayman, Christina Kannigadu, Janine Aucamp, Helena D. Janse van Rensburg, Cassiem Joseph, Andrew J. Swarts and David D. N'Da*

RESEARCH ARTICLES









RESEARCH ARTICLES

2068



Identification of novel 1,2,3-triazole isatin derivatives as potent SARS-CoV-2 3CLpro inhibitors *via* click-chemistry-based rapid screening

Xiangyi Jiang, Jing Li, Antonio Viayna, F. Javier Luque, Molly Woodson, Lanlan Jing, Shenghua Gao, Fabao Zhao, Minghui Xie, Karoly Toth, John Tavis, Ann E. Tollefson,* Xinyong Liu* and Peng Zhan*

2079



Synthesis, activity and metabolic stability of propan-2-one substituted tetrazolylalkanoic acids as dual inhibitors of cytosolic phospholipase $A_2\alpha$ and fatty acid amide hydrolase

Merlin Ekodo Voundi, Walburga Hanekamp and Matthias Lehr*

2089



Naphthylthiazoles: a class of broad-spectrum antifungals

Mohamed Hagras,* Nader S. Abutaleb, Hany G. Ezzat, Ehab A. Salama, Mohamed N. Seleem and Abdelrahman S. Mayhoub*

2100



Design, synthesis, and biological evaluation of 3,3′-diindolylmethane *N*-linked glycoconjugate as a leishmanial topoisomerase IB inhibitor with reduced cytotoxicity

Parampreet Kour, Pallavi Saha, Srija Bhattacharya, Diksha Kumari, Abhipsa Debnath, Amit Roy, Deepak K. Sharma, Debaraj Mukherjee* and Kuljit Singh*